NICE has recommended eltrombopag olamine (Revolade, GSK) as an option for treating some adults with the bleeding disorder chronic immune (idiopathic) thrombocytopenic purpura in final guidance. NICE has recommended eltrombopag as a treatment option only if they have severe disease and a high risk of bleeding that needs frequent courses of rescue therapies and if GSK makes it available to the NHS under the terms agreed with the Department of Health as part of a patient access scheme. For more details, go to: http://www.nice.org.uk/newsroom/pressreleases/NICESaysYesToBloodDisorderTreatmentInFinalGuidance.jsp